title: Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons.
abstract: The kynurenine pathway (KP) is the principle route of L-Tryptophan (TRP) metabolism, producing several neurotoxic and neuroprotective metabolic precursors before complete oxidation to the essential pyridine nucleotide nicotinamide adenine dinucleotide (NAD(+)). KP inhibition may prove therapeutic in central nervous system (CNS) inflammation by reducing the production of excitotoxins such as quinolinic acid (QUIN). However, KP metabolism may also be cytoprotective through the de novo synthesis of intracellular NAD(+). We tested the hypothesis that the KP is directly involved in the maintenance of intracellular NAD(+) levels and SIRT1 function in primary astrocytes and neurons through regulation of NAD(+) synthesis. Competitive inhibition of indoleamine 2,3 dioxygenase (IDO), and quinolinic acid phosphoribosyltransferase (QPRT) activities with 1-methyl-L-Tryptophan (1-MT), and phthalic acid (PA) respectively, resulted in a dose-dependent decrease in intracellular NAD(+) levels and sirtuin deacetylase-1 (SIRT1) activity, and correlated directly with reduced cell viability. These results support the hypothesis that the primary role of KP activation during neuroinflammation is to maintain NAD(+) levels through de novo synthesis from TRP. Inhibition of KP metabolism under these conditions can compromise cell viability, NAD-dependent SIRT1 activity and CNS function, unless alternative precursors for NAD(+) synthesis are made available.
authors.affiliation: University of New South Wales, Faculty of Medicine, Sydney, Australia.
authors.forename: Nady
authors.initials: N
authors.lastname: Braidy
authors.forename: Gilles J
authors.initials: GJ
authors.lastname: Guillemin
authors.forename: Ross
authors.initials: R
authors.lastname: Grant
references.citation: Physiology (Bethesda). 2006 Dec;21:404-10
references.pmid: 17119153
references.citation: Expert Opin Ther Targets. 2009 Aug;13(8):987-1012
references.pmid: 19534572
references.citation: Int J Biochem Cell Biol. 2005 Feb;37(2):289-305
references.pmid: 15474976
references.citation: Schizophr Bull. 2010 Mar;36(2):211-8
references.pmid: 20147364
references.citation: PLoS One. 2009 Jul 22;4(7):e6344
references.pmid: 19623258
references.citation: J Mol Med (Berl). 2007 Dec;85(12):1351-9
references.pmid: 17594069
references.citation: Antioxid Redox Signal. 2008 Feb;10(2):179-206
references.pmid: 18020963
references.citation: Adv Enzymol Relat Areas Mol Biol. 1999;73:135-82, xi
references.pmid: 10218108
references.citation: Trends Pharmacol Sci. 2000 Apr;21(4):149-54
references.pmid: 10740291
references.citation: Biochem Biophys Res Commun. 1986 Jan 14;134(1):227-32
references.pmid: 3080986
references.citation: Neurotox Res. 2008 May-Jun;13(3-4):173-84
references.pmid: 18522897
references.citation: Toxicon. 2001 Jan;39(1):61-73
references.pmid: 10936623
references.citation: Neuropathol Appl Neurobiol. 2005 Aug;31(4):395-404
references.pmid: 16008823
references.citation: Redox Rep. 2002;7(4):199-206
references.pmid: 12396664
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: J Neurochem. 2001 Aug;78(4):842-53
references.pmid: 11520905
references.citation: Cell Mol Life Sci. 2005 Apr;62(7-8):751-9
references.pmid: 15868400
references.citation: Cell Physiol Biochem. 2007;20(1-4):45-54
references.pmid: 17595514
references.citation: Int J Tryptophan Res. 2009;2:61-9
references.pmid: 22084582
references.citation: J Neurochem. 1985 Jul;45(1):199-205
references.pmid: 2582090
references.citation: Adv Exp Med Biol. 2002;513:249-80
references.pmid: 12575824
references.citation: Mol Biol Cell. 2005 Oct;16(10):4623-35
references.pmid: 16079181
references.citation: Metab Brain Dis. 2007 Dec;22(3-4):337-52
references.pmid: 17712616
references.citation: Nat Rev Drug Discov. 2002 Aug;1(8):609-20
references.pmid: 12402501
references.citation: Neurotox Res. 2009 Jul;16(1):77-86
references.pmid: 19526301
references.citation: J Interferon Cytokine Res. 2001 Dec;21(12):1097-101
references.pmid: 11798468
references.citation: J Biol Chem. 1986 Mar 15;261(8):3648-53
references.pmid: 2419335
references.citation: Adv Exp Med Biol. 2003;527:137-45
references.pmid: 15206726
references.citation: Curr Opin Chem Biol. 2008 Feb;12(1):11-7
references.pmid: 18282481
references.citation: Neurodegener Dis. 2005;2(3-4):166-76
references.pmid: 16909022
references.citation: Curr Opin Cell Biol. 2008 Jun;20(3):303-9
references.pmid: 18468877
references.citation: Adv Exp Med Biol. 1996;398:125-9
references.pmid: 8906254
references.citation: J Neurosci Methods. 1987 May;20(1):83-90
references.pmid: 2884353
references.citation: Ann Neurol. 2005 Jan;57(1):67-81
references.pmid: 15546155
references.citation: Int J Tryptophan Res. 2010;3:151-6
references.pmid: 22084595
references.citation: Prog Neurobiol. 2001 Jun;64(2):185-218
references.pmid: 11240212
references.citation: Recent Pat CNS Drug Discov. 2008 Jan;3(1):61-9
references.pmid: 18221243
references.citation: Glia. 2005 Jan 1;49(1):15-23
references.pmid: 15390107
references.citation: Neurosci Lett. 2000 Apr 14;283(3):233-5
references.pmid: 10754231
references.citation: Exp Hematol. 2003 Jun;31(6):446-54
references.pmid: 12829019
references.citation: Free Radic Biol Med. 2000 Jul 15;29(2):191-8
references.pmid: 10980407
references.citation: Clin Chem Lab Med. 2003 Jul;41(7):852-9
references.pmid: 12940508
references.citation: J Neuroimmunol. 2002 Aug;129(1-2):186-96
references.pmid: 12161035
references.citation: J Neurochem. 1998 Apr;70(4):1759-63
references.pmid: 9523595
references.citation: J Neuroinflammation. 2005 Jul 26;2:16
references.pmid: 16042813
references.citation: Redox Rep. 2000;5(2-3):101-4
references.pmid: 10939283
references.citation: Eur J Pharmacol. 2002 Jul 5;447(2-3):285-96
references.pmid: 12151020
references.citation: Anal Biochem. 1973 Jun;53(2):452-8
references.pmid: 4351948